nach oben

Erschienen in:

2021 | Antipsychotika | OriginalPaper | Buchkapitel

3. Antipsychotika

verfasst von : Prof. Dr. med. Dr. rer. nat. Matthias J. Müller, Otto Benkert

Erschienen in: Kompendium der Psychiatrischen Pharmakotherapie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Antipsychotika im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Ein Schwerpunkt liegt in der ausführlichen Darstellung der Risiken und Nebenwirkungen der Antipsychotika.

Arasteh O, Nomani H, Baharara H et al (2020) Antipsychotic drugs and risk of developing venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis. Curr Vasc Pharmacol 18(6):632–643PubMedCrossRef

Arranz B, Garriga M, García-Rizo C, San L (2018) Clozapine use in patients with schizophrenia and a comorbid substance use disorder: a systematic review. Eur Neuropsychopharmacol 28(2):227–242PubMedCrossRef

Barnes TR, Leeson VC, Paton C et al (2017) Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technol Assess 21(49):1–56PubMedPubMedCentralCrossRef

Block TS, Kushner H, Kalin N et al (2018) Combined analysis of mifepristone for psychotic depression: plasma levels associated with clinical response. Biol Psychiatry 84(1):46–54PubMedCrossRef

Bosnjak Kuharic D, Kekin I, Hew J et al (2019) Interventions for prodromal stage of psychosis. Cochrane Database Syst Rev 2019(11):CD012236

Çakici N, van Beveren NJM, Judge-Hundal G et al (2019) An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med 49(14):2307–2319PubMedPubMedCentralCrossRef

Correll CU, Rubio JM, Inczedy-Farkas G et al (2017) Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 74(7):675–684PubMedPubMedCentralCrossRef

Demjaha A, Lappin JM, Stahl D et al (2017) Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med 47(11):1981–1989PubMedCrossRef

DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde e. V.) (Hrsg) (2019) S3-Leitlinie Schizophrenie. AWMF-Register Nr. 038-009. Langfassung, Stand: 15. März 2019. https://www.awmf.org/leitlinien/detail/ll/038-009.html

Dold M, Li C, Gillies D, Leucht S (2013) Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 23:1023–1033PubMedCrossRef

Dunk LR, Annan LJ, Andrews CD (2006) Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 188:255–263PubMedCrossRef

Galling B, Roldán A, Rietschel L et al (2016) Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf 15(5):591–612PubMedCrossRef

Galling B, Roldan A, Hagi K et al (2017) Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 16(1):77–89PubMedPubMedCentralCrossRef

Galling B, Vernon JA, Pagsberg AK et al (2018) Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand 137(3):187–205PubMedCrossRef

Ghabrash MF, Coronado-Montoya S, Aoun J et al (2020) Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: a systematic review with a risk of bias assessment. Psychiatry Res 286:112890PubMedCrossRef

Gregory A, Mallikarjun P, Upthegrove R (2017) Treatment of depression in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 211(4):198–204PubMedCrossRef

Hiemke C (2019) Concentration-effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges. Ther Drug Monit 41(2):174–179PubMedCrossRef

Howes OD, McCutcheon R, Agid O et al (2017) Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry 174(3):216–229PubMedCrossRef

Huhn M, Nikolakopoulou A, Schneider-Thoma J et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202):939–951PubMedPubMedCentralCrossRef

Kane JM, Correll CU (2016) The role of clozapine in treatment-resistant schizophrenia. JAMA Psychiatry 73(3):187–188PubMedCrossRef

Kennedy NI, Lee WH, Frangou S (2018) Efficacy of non-invasive brain stimulation on the symptom dimensions of schizophrenia: a meta-analysis of randomized controlled trials. Eur Psychiatry 49:69–77PubMedCrossRef

Krause M, Zhu Y, Huhn M et al (2018) Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatr Clin Neurosci 268(7):625–639CrossRef

Lally J, Tully J, Robertson D et al (2016) Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 171(1–3):215–224PubMedCrossRef

Lally J, McCaffrey C, O’Murchu C et al (2019) Clozapine rechallenge following neuroleptic malignant syndrome: a systematic review. J Clin Psychopharmacol 39(4):372–379PubMedCrossRef

Leucht S, Davis JM (2017) Do antipsychotic drugs lose their efficacy for relapse prevention over time? Br J Psychiatry 211(3):127–129PubMedCrossRef

Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962PubMedCrossRef

Leucht S, Samara M, Heres S et al (2014) Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40(2):314–326PubMedPubMedCentralCrossRef

Leucht S, Leucht C, Huhn M et al (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174(10):927–942PubMedCrossRef

Leucht S, Chaimani A, Mavridis D et al (2019) Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. Neuropsychopharmacology 44(11):1955–1966PubMedPubMedCentralCrossRef

Masood B, Lepping P, Romanov D, Poole R (2018) Treatment of alcohol-induced psychotic disorder (alcoholic hallucinosis) – a systematic review. Alcohol Alcohol 53(3):259–267PubMedCrossRef

Maust DT, Kim HM, Seyfried LS et al (2015) Antipsychotics, other psychotropics, and the risk of death in patients with dementia. Jama Psychiatry 72:438–445PubMedPubMedCentralCrossRef

Mizuno Y, McCutcheon RA, Brugger SP, Howes OD (2020) Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. Neuropsychopharmacology 45(4):622–631PubMedCrossRef

Okhuijsen-Pfeifer C, Huijsman EAH, Hasan A et al (2018) Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr Scand 138(4):281–288PubMedPubMedCentralCrossRef

Osoegawa C, Gomes JS, Grigolon RB et al (2018) Non-invasive brain stimulation for negative symptoms in schizophrenia: an updated systematic review and meta-analysis. Schizophr Res 197:34–44PubMedCrossRef

Pelzer AC, van der Heijden FM, den Boer E (2018) Systematic review of catatonia treatment. Neuropsychiatr Dis Treat 14:317–326PubMedPubMedCentralCrossRef

Pillinger T, Beck K, Gobjila C et al (2017) Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74(3):261–269PubMedPubMedCentralCrossRef

Pillinger T, McCutcheon RA, Vano L et al (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7(1):64–77PubMedPubMedCentralCrossRef

Sabe M, Kirschner M, Kaiser S (2019) Postdopaminergic drugs for treating the negative symptoms of schizophrenia. Systematic review and meta-analysis of randomized controlled trials.J Clin Psychopharmacol 39:658–664PubMedCrossRef

Sakurai H, Suzuki T, Bies RR et al (2016) Increasing versus maintaining the dose of olanzapine or risperidone in schizophrenia patients who did not respond to a modest dosage: a double-blind randomized controlled trial. J Clin Psychiatry 77(10):1381–1390PubMedCrossRef

Samara MT, Leucht C, Leeflang MM et al (2015) Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172:617–629PubMedCrossRef

Samara MT, Dold M, Gianatsi M et al (2016) Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. Jama Psychiatry 73(3):199–210PubMedCrossRef

Schneider-Thoma J, Efthimiou O, Huhn M et al (2018) Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry 5(8):653–663PubMedCrossRef

Sinclair DJ, Zhao S, Qi F et al (2019) Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011847.pub2CrossRefPubMedPubMedCentral

Sondergaard KB, Weeke P, Wissenberg M et al (2017) Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J Cardiovasc Pharmacother 3(2):100–107PubMed

Taylor DM, Smith L, Gee SH et al (2012) Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 125:15–24PubMedCrossRef

Tiihonen J, Mittendorfer-Rutz E, Torniainen M et al (2016) Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 173(6):600–606PubMedCrossRef

Tiihonen J, Mittendorfer-Rutz E, Majak M et al (2017) Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29.823 patients with schizophrenia. JAMA Psychiatry 74(7):686–693PubMedPubMedCentralCrossRef

Tiihonen J, Taipale H, Mehtälä J et al (2019) Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 76(5):499–507PubMedPubMedCentralCrossRef

Torniainen M, Mittendorfer-Rutz E, Tanskanen A et al (2015) Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 41:656–636PubMedCrossRef

Williams AM (2018) Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness. Ment Health Clin 8(5):208–213PubMedPubMedCentralCrossRef

Wimberley T, MacCabe JH, Laursen TM et al (2017) Mortality and selfharm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 174:990–998PubMedCrossRef

Yoshimura B, Sakamoto S, Sato K et al (2017) Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: secondary analysis of an observational study. Early Interv Psychiatry 250:65–70

Yunusa I, Alsumali A, Garba AE et al (2019) Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open 2(3):e190828PubMedPubMedCentralCrossRef

Zeller S, Zun L, Cassella JV et al (2017) Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses. BJPsych open 3(6):285–290PubMedPubMedCentralCrossRef

Titel: Antipsychotika
verfasst von: Prof. Dr. med. Dr. rer. nat. Matthias J. Müller
Otto Benkert
Verlag: Springer Berlin Heidelberg
Buch: Kompendium der Psychiatrischen Pharmakotherapie
Print ISBN: 978-3-662-61752-6

Electronic ISBN: 978-3-662-61753-3

Copyright-Jahr: 2021
DOI: https://doi.org/10.1007/978-3-662-61753-3_3

Neu im Fachgebiet Psychiatrie

23.04.2024 | Demenz | Nachrichten

Springer Medizin

3. Antipsychotika

Zusammenfassung

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein